JNCI Journal of the National Cancer Institute · 2016 · 209 citations · 19 references
MedicineBiostatisticsOncologyBreast OncologyEndocrine OncologyMolecular OncologyBreast Cancer RecurrenceBreast Cancer Risk AssessmentCancer BiomarkersCancer Survival AnalysisHer2-positive Breast CancerMalignant NeoplasmsBreast Cancer PrognosisCancer Recurrence RiskClinical Risk Prediction ToolsClinicopathologic FeaturesEstrogen Receptor StatusKaplan-meier Survival EstimatesPrognostic Risk AssessmentPrognostic Variables
BACKGROUND: Estimating distant recurrence (DR) risk among women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer helps decisions on using adjuvant chemotherapy. The 21-gene Oncotype DX recurrence score (RS) is widely used for this. EndoPredict (EPclin) is an alternative test combining prognostic information from an eight-gene signature (EP score) with tumor size and nodal status. We compared the prognostic information provided by RS and EPclin for 10-year DR risk. METHODS: We used likelihood ratio χ² and Kaplan-Meier survival analyses to compare prognostic information provided by EP, EPclin, RS, and the clinical treatment score (CTS) of clinicopathologic parameters in 928 patients with ER+ disease treated with five years' anastrozole or tamoxifen. Comparisons were made for early (0-5 years) and late (5-10 years) DR according to nodal status. All statistical tests were two-sided. RESULTS: In the overall population, EP and EPclin provided substantially more prognostic information than RS (LRχ(2): EP = 49.3; LRχ(2): EPclin = 139.3; LRχ(2): RS = 29.1), with greater differences in late DR and in node-positive patients. EP and EPclin remained statistically significantly prognostic when adjusted for RS (ΔLRχ(2): EP+RS vs RS = 20.2; ΔLRχ(2): EPclin+RS vs RS = 113.8). Using predefined cut-offs, EPclin and RS identified 58.8% and 61.7% patients as low risk, with hazard ratios for non-low vs low risk of 5.99 (95% confidence interval [CI] = 3.94 to 9.11) and 2.73 (95% CI = 1.91 to 3.89), respectively. CONCLUSIONS: EP and EPclin were highly prognostic for DR in endocrine-treated patients with ER+, HER2-negative disease. EPclin provided more prognostic information than RS. This was partly but not entirely because of EPclin integrating molecular data with nodal status and tumor size.
19
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik, Steven Shak, Gong Tang et al. · New England Journal of Medicine · 2004 · 6.4K citations · Full text
Medicine, Oncology, Breast Oncology +12
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano, Robert J. Gray, Della Makower et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text
Medicine, Oncology, Breast Oncology +16
Torsten O. Nielsen, Joel S. Parker, Samuel Leung et al. · Clinical Cancer Research · 2010 · 824 citations · Full text
Medicine, Biostatistics, Oncology +16
Jack Cuzick, Mitch Dowsett, Sílvia Pineda et al. · Journal of Clinical Oncology · 2011 · 744 citations
Medicine, Cancer Biology, Oncology +16